Slotman, Berend J.
Clark, Mary Ann
Özyar, Enis
Kim, Myungsoo
Itami, Jun
Tallet, Agnès
Debus, Jürgen
Pfeffer, Raphael
Gentile, PierCarlo
Hama, Yukihiro
Andratschke, Nicolaus
Riou, Olivier
Camilleri, Philip
Belka, Claus
Quivrin, Magali
Kim, BoKyong
Pedersen, Anders
van Overeem Felter, Mette
Kim, Young Il
Kim, Jin Ho
Fuss, Martin
Valentini, Vincenzo
Article History
Received: 24 March 2022
Accepted: 25 July 2022
First Online: 22 August 2022
Declarations
:
: Not applicable.
: Not applicable.
: BS—department has research agreements with Varian, Elekta and ViewRay; honorarium from ViewRay. MAC—an employee and shareholder in ViewRay, Inc. EÖ—ViewRay, Inc. speaker fees; ViewRay advisory board; ViewRay Consulting fees. MK—The author declares that there is no competing interest. JI—Grant from ITOCHU, and Eleka. Consultation fee from HekaBio, AlphaTau, and Palette Science. AT—Department has research support from ViewRay and Qualimedis. JD—Grants from ViewRay, Inc.; Accuray International Sari; Raysearch Laboratories AB; Vision RT Limited; Merck Serono GmbH; Astellas Pharma GmbH; Siemens Healthcare GmbH; Solution Akademie GmbH; Egomed PLC Surrey Research Park; Quintiles GmbH; Pharmaceutical Research Associates GmbH; Boehringer Ingelheim Pharma GmbH&CoKG; PTW-Freiburg Dr. Pychlau GmbH; Nanobiotix S.A.; Accuray Incorporated. RP—The author declares that there is no competing interest. PG—The author declares that there is no competing interest. YH—The author declares that there is no competing interest. NA—research support from: ViewRay, Brainlab. Speaker’s and advisory compensation: ViewRay, Deiobpharm, AstraZeneca. OR—Department has research support from ViewRay and Qualimedis. PC—shareholder GenesisCare; leadership role GenesisCare UK; payment or honoraria from Ipsen, AstraZeneca, and GenesisCare Spain. CB—Grants from ViewRay, BrainLab, Elekta; Payment or honoraria from Elekta, BrainLab, C-RAD, Merck, Merck Sharp & Dohme (MSD), Roche, Astra-Zeneca, Bristol Myers Squibb (BMS); Support for attending meetings and/or travel from MSD, Roche, Astra-Zeneca, BMS, Merck; Participation in a Data Safety Monitoring Board or Advisory Board—BMS, MSD, Astra-Zeneca. MQ—Department has research support from ViewRay and Qualimedis. BK—The author declares that there is no competing interest. AP—The author declares that there is no competing interest. MvOF—PhD project is sponsored by Varian Medical Systems. YIK—The author declares that there is no competing interest. JHK—ViewRay speaker fee. MF—an employee and shareholder in ViewRay, Inc. VV—department has research support from ViewRay.